



Scimago Journal & Country Rank

Enter Journal Title, ISSN or Publisher Name

- Home
- Journal Rankings
- Country Rankings
- Viz Tools
- Help
- About Us

**New subscriptions only**

**Subscribe To Nature Journal**

Get your 1-year Nature subscription at only \$ / € / £ 99


promo.nature.com OPEN

# Drug Invention Today

Discontinued in Scopus as of 2020

COUNTRY

India

 Universities and research institutions in India

SUBJECT AREA AND CATEGORY

Pharmacology, Toxicology and  
Pharmaceutics  
Drug Discovery

PUBLISHER

Association of Pharmaceutical Innovators

H-INDEX

# 20

PUBLICATION TYPE

▼ Journals

ISSN

09757619

COVERAGE

2012-2021





Evolve your PCR with KAPA Biosystems



**Drug Invention Today**

Not yet assigned quartile

SJR 2021  
0

powered by scimagojr.com


← Show this widget in your own website

Just copy the code below and paste within your html code:

```
<a href="https://www.scimaç
```

**SCImago Graphica**

Explore, visually communicate and make sense of data with our **new data visualization tool.**



**Sigma-Aldrich**

**BENCHTOP BREAKTHROUGHS**

Roche

Evolve your PCR with KAPA Biosystems



## DRUG INVENTION TODAY

ISSN NO: 0975-7619

*Drug Invention Today* (DIT) was first published in 2009 by JPR Solutions. It is a journal, which publishes reviews, research papers and short communications. From 2019 Journal will be monthly twice (vol 11& 12 with 2 Issues per month)

• Novel Drug Delivery Systems • Nanotechnology & Nanomedicine • Biotechnology related pharmaceutical technology • Polymeric bio-conjugates • Biological macromolecules • Biomaterials • Drug Information • Drug discovery/development • Screening of drugs from natural & synthetic origins • Novel therapeutic strategies • Combinatorial chemistry and parallel synthesis • Clinical trials • Case Reports

Impact Factor™ (India) = 0.895 as on date (09.11.2018)

Scopus Indexed (link <http://www.scimagojr.com/journalsearch.php?q=21100202909&tip=sid&clean=0>)

Indexed in

NCBI NLM Catalogue,

SCOPUS, EMBASE (Elsevier),

SCIMAGO, CAS,

ROAD, CABI, Google Scholar,

Open J-Gate, Biblioteca,

Science Central,

Index Scholar, Indian Citation Index,

AYUSH Research Portal,

Indexed Copernicus, EBSCO, PSOAR,

Ulrichs Directory of Periodicals, etc.



**Title:** Awareness on soil pollution among school students  
**Category:** Pharmaceutics  
**Section:** Research Article  
**Author:** Department of Biochemistry, Saveetha Dental College, Saveetha Institute of Medical and  
**Affiliation:** Technical Sciences, Saveetha University, Chennai, Tamil Nadu, India



[View Article](#)

### Journal: Drug Invention Today , Volume: 11, Issue: August



**Article Id:** JPRS-P col-00003875  
**Title:** Awareness of mental health among teenagers  
**Category:** Pharmaceutics  
**Section:** Research Article  
**Author:** Department of Biochemistry, Saveetha Dental College, Saveetha Institute of Medical and  
**Affiliation:** Technical Sciences, Saveetha University, Chennai, Tamil Nadu, India



[View Article](#)

### Journal: Drug Invention Today , Volume: 11, Issue: August



**Article Id:** JPRS-P col-00003876  
**Title:** Zinc supplementation in normal conditions increases the pro-inflammatory cytokines  
**Category:** Pharmaceutics  
**Section:** Research Article  
**Author:** Department of Pathology Anatomy, Faculty of Medicine, Airlangga University, Surabaya, East  
**Affiliation:** Java, Indonesia



[View Article](#)

**Note:** The **impact factor** shown here is equivalent to **citescore** and is, therefore, used as a replacement for the same. Citescore is produced by Scopus, and can be a little higher or different compared to the impact factor produced by Journal Citation Report. Please refer to Web of Science data source for checking the exact journal impact factor™ (Thomson Reuters) metric.

<b>Title</b>	<b>Drug Invention Today</b>
<b>Publication Type</b>	<b>journal</b>
<b>Subject Area, Categories, Scope</b>	<b>Drug Discovery (Q4)</b>
<b>h-index</b>	<b>12</b>
<b>Overall Rank/Ranking</b>	<b>27761</b>
<b>SCImago Journal Rank (SJR)</b>	<b>0.108</b>
<b>Impact Factor</b>	<b>0.20</b>
<b>Publisher</b>	<b>Association of Pharmaceutical Innovators</b>
<b>Country</b>	<b>India</b>
<b>ISSN</b>	<b>09757619</b>

## Zinc supplementation in normal conditions increases the pro-inflammatory cytokines

Martono T. Utomo<sup>1\*</sup>, Subijanto M. Sudarmo<sup>1</sup>, Ketut Sudiana<sup>2</sup>

### ABSTRACT

**Background:** Zinc supplementation in young adults has been found to increase dose-dependent pro-inflammatory cytokines. Increased proinflammatory cytokine has been found in severe sepsis and shock conditions. To determine the effect of zinc administration on normal conditions on pro-inflammatory cytokines compared to sepsis and normal conditions. **Methods:** A total sample of 40 rats was randomized into four control groups, lipopolysaccharide (LPS), LPS-zinc, and zinc. Placebo normal saline was given intravenously to the control and zinc groups, whereas in the LPS and LPS-zinc groups, intravenous *Escherichia coli* LPS was given. Blood collection was carried out at the 2nd h after administration to measure zinc levels, and an oral distilled water placebo was given to the control group and LPS, while the LPS-zinc and zinc groups were given zinc supplementation orally for 3 days. At 8, 24, and 72 h, blood was collected to measure tumor necrosis factor-alpha (TNF- $\alpha$ ) and interleukin-6 (IL-6) levels. At the 72nd h, blood was also taken to measure zinc levels. Examination of TNF- $\alpha$  and IL-6 levels used the enzymelinked immunosorbent assay Sandwich technique, while zinc levels used atomic absorption spectroscopy. **Results:** The TNF- $\alpha$  level in the zinc group at 72nd h was higher than the control group, while the zinc group's IL-6 level was higher than the control group at 8th and 24th h. The levels of TNF- $\alpha$  and IL-6 in the zinc group were lower than LPS and LPS-zinc groups. **Conclusions:** Zinc supplementation under normal conditions increases the cytokines of TNF- $\alpha$  and IL-6. **KEY WORDS:** Interleukin-6, Normal conditions, Tumor necrosis factor-alpha, Zinc.

**KEY WORDS:** Interleukin-6, Normal conditions, Tumor necrosis factor-alpha, Zinc

### INTRODUCTION

Zinc supplementation has been used as an additional therapy for certain conditions, namely, sepsis, diarrhea, and pneumonia, often resulting in a decrease in the incidence and mortality rate of these diseases.<sup>[1,2]</sup> Zinc supplementation has been used several conditions, such as sepsis, malnutrition, diarrhea, sickle cell disease, and in the elderly.<sup>[3-6]</sup> Zinc supplementation in sickle cell patients can reduce levels of tumor necrosis factor-alpha (TNF- $\alpha$ ); in the elderly, a decrease in TNF- $\alpha$ , oxidative stress, and increased interleukin-2 (IL-2) were seen.<sup>[5,6]</sup> Further, zinc supplementation in healthy older subjects can increase immune reactions to invading pathogens. Mild zinc deficiencies can be found in the elderly.<sup>[7]</sup> In healthy young subjects, zinc supplementation can increase the expression of TNF- $\alpha$  and IL-1b when monocytes of subjects are exposed to lipopolysaccharides (LPSs).<sup>[8]</sup>

The pro-inflammatory effects of zinc are mediated through tyrosine phosphorylation and induction of protein kinase C. Tyrosine phosphorylation is used for signal induction of toll-like receptor (TLR)-4 by LPSs. Tyrosine phosphorylation is performed by protein tyrosine kinase (PTK) and is degraded by protein tyrosine phosphatase (PTP); zinc is a potent inhibitor of PTP.<sup>[9]</sup> Zinc also has the direct effect of stimulating monocytes to secrete IL-1, IL-6, TNF- $\alpha$ , and interferon gamma (IFN- $\gamma$ ).<sup>[9,10]</sup>

TNF- $\alpha$  and IL-6 are pro-inflammatory cytokines that can distinguish survivors and non-survivors at 28 days and as predictors of shock sepsis, multiple organ failure and disseminated intravascular coagulation.<sup>[11]</sup> Increased IL-6 in severe sepsis caused increased capillary leakage and decreased intestinal contraction.<sup>[12,13]</sup> TNF- $\alpha$  has an essential role in inflammation, and administration of recombinant human (rh-TNF) in experimental animals can cause symptoms of hypotension, metabolic acidosis, massive pulmonary bleeding, acute tubular necrosis in the kidneys, and gastrointestinal bleeding lesions.<sup>[14,15]</sup>

#### Access this article online

Website: [jprsolutions.info](http://jprsolutions.info)

ISSN: 0975-7619

<sup>1</sup>Department of Child Health, Faculty of Medicine, Airlangga University, Surabaya, East Java, Indonesia, <sup>2</sup>Department of Pathology Anatomy, Faculty of Medicine, Airlangga University, Surabaya, East Java, Indonesia

\*Corresponding author: Martono T. Utomo, Department of Child Health, Faculty of Medicine, Airlangga University, Surabaya, East Java, Indonesia. E-mail: [martono-t-u@fk.unair.ac.id](mailto:martono-t-u@fk.unair.ac.id)/[mrmartono73@gmail.com](mailto:mrmartono73@gmail.com)

Received on: 14-02-2019; Revised on: 26-03-2019; Accepted on: 29-04-2019

Zinc supplementation in sepsis induced by intravenous *Escherichia coli* LPSs can reduce levels of pro-inflammatory cytokines TNF- $\alpha$  and IL-6, improving the condition of sepsis in the sepsis group given zinc.<sup>[16]</sup> Zinc administration in healthy young adults can increase pro-inflammatory cytokine in a dose-dependent manner.<sup>[17]</sup> The purpose of this study was to examine the effect of zinc supplementation in normal subjects on proinflammatory cytokine levels.

## MATERIALS AND METHODS

### Preparation of Animal Study

This study was given ethical clearance, number 700-KEP-UB. This study used 40 Dawley Sprague rats aged 10–12 weeks, which were acclimatized for 2 weeks at the University of Brawijaya Bioscience Institute before being used as experimental animals. Rats were kept in a wire-covered, ventilated plastic enclosure, on a 12-h bright lighting/12 h dark cycle and equipped with a place to eat and drink. The rats were fed standard pellets and drank water *ad libitum*, and husk bedding was replaced every 2 days. Before treatments, the rats were allocated randomly to four groups, namely, control, LPS, LPS-zinc, and zinc, with ten animals each. The same method was also used in a previous study.<sup>[16]</sup>

Provision of LPS *E. coli* serotype O11: B4 Sigma at a dose of 10 mg/kg intravenously was done using a 500 mg preparation; 100 mg of the preparation was diluted with 10 mL distilled water and injected into rats in the LPS and LPS zinc groups in 0.2 mL doses. The control group and zinc group were given normal saline 0.2 mL intravenously. To facilitate intravenous injection, a 0.1 mL intramuscular ketamine injection was given. After 2 h, blood from five rats was collected to measure the zinc serum concentration, using the measuring technique described below.

Oral administration of zinc was done by mixing 1 mL of 10 mg/mL of zinc sulfate and 9 mL distilled water to make the content of 1 mg/mL. Zinc was given at a dose of 2 mg/kg body weight (which is comparable with 4.65 mg/kg BB rats through the sonde in the 1 mL LPS zinc and zinc group) while the control group and LPS were given 1 mL distilled water. At the 8<sup>th</sup> h postadministration, blood was collected, and the level of TNF- $\alpha$  and IL-6 was measured using enzyme-linked immunosorbent assay (ELISA) as described below. The previous steps were done again after 24 h and 48 h. At the 48<sup>th</sup> h, blood was collected to measure the zinc, TNF- $\alpha$ , and IL-6 levels.

### Serum Collection

As noted above, at 2<sup>nd</sup> h, 2 mL of blood was withdrawn through the tail veins of the rats in the first five rats in each group to check the zinc levels. At h 8 and h 24, 2 mL of blood was withdrawn in the same manner in

the second five rats of each group to check the TNF- $\alpha$  and IL-6 cytokine levels. The groups were split to avoid shock conditions in the animal from too-frequent blood withdrawals. At the end of the experiment (72 h), blood was taken from the heart and the aorta after the rats were killed and check for zinc, TNF- $\alpha$  IL-6 levels.

The withdrawn blood was inserted in the tube without EDTA and then centrifuged 6,000 x g for 10 min. The serum was removed and left at 25°C in 30 min then stored in the freezer at -20°C.

### Serum Zinc Level

Zinc content was examined by atomic absorption spectrophotometry (AAS) by Smith *et al.*<sup>[18]</sup> For AAS, 1000 mg of zinc per liter standard were made: 10 mL of nitric acid was diluted to 50 mL, into which 1.000 g of zinc metal was added and dissolved and further diluted to 100 mL. (b) Working standards, 100, 200, 300, and 400  $\mu$ g of zinc per liter were prepared: 1 mL of 1000 mg/L zinc standard were added into a 100-mL volumetric flask and diluted to volume with a glycerol/water solution (5/95 by vol), and mixed by inverting at least 16 times. Aliquots of this common stock (1, 2, 3, and 4 mL) were placed into four 100-mL volumetric flasks and dilute to volume with the glycerol/water mixture. The standards (0.1, 0.2, 0.3, and 0.4 mg of zinc per liter) correspond to apparent plasma zinc concentrations of 500, 1000, 1500, and 2000  $\mu$ g of zinc per liter. A working curve was prepared daily from fresh standards, and the concentration of zinc in the plasma was calculated directly from the curve.

To determine serum zinc levels, 2 mL of whole blood was collected in a tube by cutting the tip of the rat tail. Two drops (~50  $\mu$ L) of a 300 g/L sodium citrate solution were added to the tube before collecting the specimen of blood. The blood was centrifuged promptly at 6000  $\times$  g for 10 min. A total of 0.5 mL of plasma sample was delivered with a serological pipette into a 16 mm plastic test tube. Next, 2.0 mL of de-ionized water was added and immediately mixed into the solution for 30 s. The zinc levels were then read with the spectrophotometry to compare with the standard.

### Cytokine Analysis

Pro-inflammatory cytokine concentrations of TNF- $\alpha$  and IL-6 were carried out by the sandwich-ELISA method by the manuals of the FineTest ELISA Manual Kit Kit instruction from Wuhan Fine Biological Technology Co., Ltd. The ELISA kit of Rat IL-6 code ER0042 size 96 T batch R0042C046 and Rat TNF- $\alpha$  ELISA Kit code ER1393 size 96 T batch R1393C064 were used in this study.

### Assay procedure

Before adding reagents into wells, tetramethylbenzidine substrate was equilibrated for 30 min at 37°C.

Standard, test sample and control (zero) wells were set on the pre-coated plate with antibody anti-TNF- $\alpha$  and IL-6 respectively, and then, their positions recorded. Each standard and sample was measured in duplicate. The plate was washed 2 times before adding standard, sample, and control (zero) wells. Next, 0.1 ml of 1000, 500, 250, 125, 62.5, 31.25, and 15.625 pg/mL standard solutions were added into the standard wells. Then, 0.1 ml of Sample/Standard Dilution Buffer was added into the control (zero) well. Finally, 0.1 ml of properly diluted rat serum was added to the test sample wells. The plate was sealed with a cover and incubated at 37°C for 90 min. The cover was removed and the plate contents discarded, and the plate was washed 2 times with wash buffer.

Next, 0.1 ml biotin-labeled antibody working solution was loaded into the standard, test sample, and zero wells. The solution was added to the bottom of each well without touching the sidewalls. The plate was sealed with a cover and incubated at 37°C for 60 min. The cover was removed, and the plate washed plate 3 times with wash buffer, with the buffer allowed to stay in the wells for 1 min each time. A total of 0.1 ml of SABC working solution was added into each well; then, the plate was covered and incubated at 37°C for 30 min. The plate was washed 5 times with wash buffer, and the wash buffer allowed to stay in the wells for 1–2 min each time.

A total of 90  $\mu$ l TMB substrate was added into each well, the plate covered and incubated at 37°C in

the dark for 15–30 min. It will turn blue in the first 3–4 wells. Next, 50  $\mu$ l stop solution was added into each well and mixed thoroughly. The color changed to yellow immediately. The optical density (O. D.) absorbance at 450 nm in a microplate reader was read immediately after adding the stop solution. The relative O. D. at 450 nm was calculated as the O. D. 450 nm of each well – the O. D. 450 nm of the zero well. The standard curve can be plotted as the relative O. D. 450 nm of each standard solution (Y) versus the particular concentration of the standard solution (X). The TNF- $\alpha$  and IL-6 concentration of the samples can be interpolated from the standard curve.

### Statistical Analysis

Data are presented as mean + standard deviation. One-way ANOVA analyzed data in the four groups and *post hoc* tests if the distribution was normal; whereas if the data were not normal then the Kruskal–Wallis test was used. Data at 8<sup>th</sup>, 24<sup>th</sup>, and 72<sup>nd</sup> h were analyzed by ANOVA if normally distributed and the Friedman test if not normally distributed. The t-dependent test analyzed zinc level data at 2 and 72 h. SPSS v. 21 (IBM, New York, United States) were used for the analyses.

## RESULTS

In this study, each group of samples contained five rats and was done in duplicate to obtain enough blood for the analyses. The 2-h samples reflected the condition of zinc serum after LPS and placebo administration; the 8-h samples showed the effect of zinc on the pro-inflammatory cytokine levels. These groups are comparable, as Table 1 and Figure 1 shows that there were no differences in the body weight of the rats in the four groups.

The 3-day zinc supplementation significantly increased zinc serum levels in the zinc group. From Table 2 and Figure 2, the results showed that zinc levels at h 2 were not different between the four groups, but found an increase in zinc level at h 72 compared to the 2<sup>nd</sup> h in the LPS, LPS-zinc, and zinc groups. At h 72, zinc levels in the zinc group were significantly increased compared to the other three groups, which showed that administering zinc for 3 days was able to increase substantially zinc levels.




Figure 1: Mean body weights of the treatment groups


Table 1: Mean rat body weights in the four treatment groups

Group	n	Body weight (g)			P
		Mean $\pm$ SD	Minimum	Maximum	
Control	5	221.40 $\pm$ 6.50	213	229	0.336
LPS	5	240.80 $\pm$ 10.50	225	253	
LPS-Zinc	5	226.60 $\pm$ 19.46	208	256	
Zinc	5	232.80 $\pm$ 24.81	201	263	


SD: Standard deviation, LPS: Lipopolysaccharide

Table 3 and Figure 3 show that in the zinc group and the control there was no difference of TNF- $\alpha$  level at the 8<sup>th</sup> and 24<sup>th</sup> h, whereas at the 72<sup>nd</sup> h there was a difference in the levels of TNF- $\alpha$ , which were higher in the zinc group compared to the controls, but the levels were still lower than in the LPS group and LPS-zinc.

From Table 4 and Figure 4 shows IL-6 levels in the zinc group were higher than the control group at 8<sup>th</sup> and



**Figure 2:** Serum zinc levels at h 2 and 72 after administration. \*Significant at  $\alpha = 0.05$ ; <sup>a,b</sup>Same letters in same hour showed no difference between groups (multiple comparisons least significant difference); \*\*Significant at  $\alpha = 0.05$  (Paired *t*-test/Wilcoxon signed-rank test)



**Figure 3:** Tumor necrosis factor-alpha levels in treatments after 8, 24, and 72 h. \*Significant at  $\alpha = 0.05$ ; <sup>a,b,c,d</sup>Same letters in the same hour revealed no difference between groups (multiple comparisons Games-Howell/Mann-Whitney)

24<sup>th</sup> h, but lower than the LPS and LPS-zinc groups. At 72 h, the IL-6 level in the zinc group did not differ significantly from the control group. This showed the effect of zinc administration in normal conditions, in that there was an increase in levels of IL-6 cytokines at 8 and 24 h, but the effect disappeared at 72 h.

## DISCUSSION

Zinc supplementation for 3 days can increase zinc levels in rats previously given a diet that is deficient in zinc.<sup>[19]</sup> Increased plasma zinc levels were also seen in other studies but with a longer duration of administration of 2–4 months.<sup>[3,18-21]</sup> Zn Transporter (ZnT) lowers intracellular zinc by efflux from cells or influx to intracellular vesicles so that extracellular or plasma levels increase, while Zrt-and Irt-like protein (ZIP) promotes zinc transport from extracellular fluid or intracellular vesicles to the cytoplasm so that cytoplasmic levels increase. ZnT1 messenger RNA (mRNA) levels in leukocytes increased significantly after Zn supplementation, resulting in an increase in serum zinc because ZnT promotes cell efflux from cells to extracellular or to blood circulation.<sup>[22]</sup> Zinc can stimulate monocytes directly to secrete TNF- $\alpha$ .<sup>[9]</sup> Zinc exposure of >100  $\mu$ M in monocyte cells can increase levels of TNF- $\alpha$ .<sup>[23]</sup>

Pro-inflammatory cytokine levels of TNF- $\alpha$  in the zinc group were higher than the control group at 72 h while IL-6 cytokines in the zinc group were higher than controls at 8<sup>th</sup> and 24<sup>th</sup> h, whereas at 72<sup>nd</sup> h there were no differences between controls and zinc group for IL-6 levels. TNF- $\alpha$  levels and IL-6 zinc groups were lower than the LPS and LPS-zinc groups.

In this study, zinc administration under normal conditions could increase the levels of proinflammatory cytokines TNF- $\alpha$  and IL-6. TNF- $\alpha$  has an essential role in inflammation and administration of rh-TNF in experimental animals can cause symptoms of hypotension, metabolic acidosis, massive pulmonary bleeding, acute tubular necrosis in the kidneys, and gastrointestinal bleeding lesions.<sup>[14,15]</sup> Zinc supplementation can increase TNF- $\alpha$  levels. In a study conducted by Chu *et al.* in type 2 diabetes mellitus patients, it was found that TNF- $\alpha$  mRNA increased.<sup>[24]</sup> The same thing was also found in the study conducted by

**Table 2: Plasma zinc levels at 2 h and 72 h after *Escherichia coli* lipopolysaccharide administration**

Group	n	Plasma zinc (mg/L)		P
		2 h	72 h	
Control	5	0.87±0.09 (0.75–0.97)	0.91±0.22 <sup>a</sup> (0.57–1.19)	0.670
LPS	5	0.62±0.21 (0.42–0.97)	1.14±0.24 <sup>a</sup> (0.94–1.54)	0.039**
LPS-Zinc	5	0.75±0.06 (0.71–0.86)	0.99±0.07 <sup>a</sup> (0.94–1.11)	0.043**
Zinc	5	0.87±0.18 (0.62–1.12)	1.49±0.17 <sup>b</sup> (1.33–1.74)	0.001**
P		0.073	0.001*	

\*Significant at  $\alpha=0.05$ , \*\*Significant at  $\alpha=0.05$  (paired *t*-test/Wilcoxon Signed-rank test), <sup>a,b</sup>Same superscript in one column showed no difference between groups (multiple comparisons LSD). LPS: Lipopolysaccharide, LSD: Least significant difference



**Table 3: Tumor necrosis factor- $\alpha$  plasma concentration at 8, 24, and 72 h**


Group	n	TNF- $\alpha$ plasma concentration (pg/mL)			P
		8 h	24 h	72 h	
Control	5	79.95 $\pm$ 2.04 <sup>a</sup> (76.55–81.55)	81.55 $\pm$ 1.30 <sup>a</sup> (80.55–84.05)	76.35 $\pm$ 3.19 <sup>a</sup> (71.55–80.55)	0.029**
LPS	5	122.55 $\pm$ 11.40 <sup>c</sup> (111.55–136.55)	110.05 $\pm$ 5.48 <sup>c</sup> (106.55–119.05)	108.05 $\pm$ 4.87 <sup>d</sup> (101.55–114.05)	0.034**
LPS-Zinc	5	92.75 $\pm$ 1.25 <sup>b</sup> (91.55–94.55)	95.35 $\pm$ 2.17 <sup>b</sup> (91.55–96.55)	93.35 $\pm$ 2.49 <sup>c</sup> (91.55–96.55)	0.211
Zinc	5	77.85 $\pm$ 4.15 <sup>a</sup> (71.55–81.55)	76.55 $\pm$ 6.12 <sup>a</sup> (71.55–86.55)	82.35 $\pm$ 4.27 <sup>b</sup> (76.55–86.55)	0.101
P		0.000*	0.001*	0.001*	

\*Significant at  $\alpha=0.05$  (Brown–Forsythe/Kruskal–Wallis), \*\*Significant at  $\alpha=0.05$  (same-subject ANOVA/ANOVA Friedman), <sup>a,b,c,d</sup>Same superscript in a column revealed no difference between groups (multiple comparisons Games–Howell/Mann–Whitney). TNF: Tumor necrosis factor, LPS: Lipopolysaccharide

**Table 4: Interleukin-6 plasma concentration at 8, 24, and 72 h**

Group	n	IL-6 plasma concentration (pg/mL)			P
		8 h	24 h	72 h	
Control	5	1.58 $\pm$ 0.09 <sup>a</sup> (1.42–1.64)	1.39 $\pm$ 0.11 <sup>a</sup> (1.31–1.55)	1.57 $\pm$ 0.05 <sup>a</sup> (1.53–1.63)	0.091
LPS	5	4.91 $\pm$ 0.40 <sup>c</sup> (4.25–5.21)	5.57 $\pm$ 0.16 <sup>d</sup> (5.54–5.93)	3.39 $\pm$ 0.38 <sup>c</sup> (3.09–4.05)	0.000**
LPS-Zinc	5	2.15 $\pm$ 0.09 <sup>b</sup> (2.06–2.25)	3.83 $\pm$ 0.19 <sup>c</sup> (3.64–4.11)	2.51 $\pm$ 0.15 <sup>b</sup> (2.34–2.74)	0.000**
Zinc	5	2.10 $\pm$ 0.17 <sup>b</sup> (1.91–2.27)	2.21 $\pm$ 0.44 <sup>b</sup> (1.81–2.72)	1.84 $\pm$ 0.26 <sup>a</sup> (1.55–2.14)	0.304
P		0.000*	0.000*	0.001*	

\*Significant at  $\alpha=0.05$  (Brown–Forsythe/Kruskal–Wallis), \*\*Significant at  $\alpha=0.05$  (Same subject ANOVA), <sup>a,b,c,d</sup>Same superscript in a column revealed no difference between groups (multiple comparisons Games–Howell/Mann–Whitney). IL: Interleukin, LPS: Lipopolysaccharide



**Figure 4:** Interleukin-6 levels in treatments at 8, 24, and 72 h. \*Significant at  $\alpha = 0.05$ ; <sup>a,b,c,d</sup>Same letters in the same hour revealed no difference between groups (multiple comparisons Games-Howell/Mann–Whitney)

Meksawan *et al.*, i.e., an increase in TNF- $\alpha$  in monocyte and lymphocyte transmembrane, which was useful as an immune response to cancer, but plasma TNF- $\alpha$  did not increase.<sup>[25]</sup> Zinc supplementation can increase NF $\kappa$ B activation through tyrosine phosphorylation and induction of protein kinase C. Tyrosine phosphorylation is used for signal induction of TLR-4 by LPSs. Tyrosine phosphorylation is performed by PTK and is degraded by PTP, and zinc is a potent inhibitor of PTP.<sup>[9]</sup> Activation of NF $\kappa$ B after administration of zinc then downstream inflammatory mediators TNF- $\alpha$ , IL-6, IL-1b, and IL-8.<sup>[26]</sup>

The increase in the IL-6 levels of the zinc group in this study occurred at the 72<sup>nd</sup> h. Increased IL-6 can determine SIRS due to infection and is associated with mortality.<sup>[27,28]</sup> IL-6 increases also occur in severe

sepsis and cause an increase in the capillary leak and decrease in intestinal contractions.<sup>[12,13]</sup> In this study, there was an increase in IL-6 in the zinc group compared to controls, but it was still lower than the LPS and LPS-zinc groups so that severe symptoms also did not appear. This is by previous studies that showed an increase in IL-6 in monocyte cell groups exposed to 100  $\mu$ M zinc content and above, whereas 30  $\mu$ M zinc exposure did not increase IL-6.<sup>[23]</sup>

Low zinc levels and increased IL-6, IL-8, IL-1g, and TNF- $\alpha$  cytokines occur in sepsis compared to healthy individuals.<sup>[29]</sup> Low plasma zinc levels in sepsis are caused by the influence of pro-inflammatory cytokines including IL-1g and IL-6, which activate STAT-mediated signals and upregulation of ZIP14 and ZIP6, which trigger plasma zinc influx into the intracellular.<sup>[22]</sup>

LPS enters the system and then is recognized by TLR4 of monocytes and is transmitted through signal transduction, which activates nuclear factor kappa B (NF $\kappa$ B).<sup>[30]</sup> Activated NF $\kappa$ B induces the expression of cytokines IL-6,<sup>[31]</sup> IL-8,<sup>[32]</sup> and TNF- $\alpha$ .<sup>[33]</sup> LPS is bound by LPS-binding protein which is captured by TLR-4 on cell membranes than through signal MyD88, IRAKs, and recruitment of adaptors TRAF6 then recruits IKK complex lead to phosphorylation and degradation of I $\kappa$ B inhibitors. NF $\kappa$ B is active and translocated to the nucleus to activate the pro-inflammatory cytokine gene.<sup>[34]</sup>

In a review conducted by Foster and Samman of several studies, it was found that zinc supplementation in normal adult conditions for 8 weeks increased IL-2, TNF- $\alpha$ , and IFN-g whereas in elderly it was found that zinc supplementation for 48 days increased plasma IL-6 levels.<sup>[17]</sup>

## CONCLUSION

Zinc supplementation under normal conditions increases proinflammatory cytokines TNF- $\alpha$  and IL-6, so it needs caution and needs to monitor clinically for zinc supplementation under normal circumstances. From this study, we suggested that zinc supplementation in normal condition should be used by cautions because it can increase the pro-inflammatory cytokine.

## ACKNOWLEDGMENT

We thank our colleagues from Bioscience Institute Brawijaya University who provided insight and expertise that greatly assisted the research, although they may not agree with all of the interpretations/conclusions of this paper.

## REFERENCES

- Black RE. Zinc deficiency, infectious disease and mortality in the developing world. *J Nutr* 2003;133:1485S-9S.
- Fischer Walker CL, Ezzati M, Black RE. Global and regional child mortality and burden of disease attributable to zinc deficiency. *Eur J Clin Nutr* 2009;63:591-7.
- Ganatra HA, Varisco BM, Harmon K, Lahni P, Opoka A, Wong HR. Zinc supplementation leads to immune modulation and improved survival in a juvenile model of murine sepsis. *Innate Immun*. 2017;23(1):67-76.
- As'ad S, Yusuf I. The effects of zinc supplementation on the TNF- $\alpha$  profile and diarrhea in severely malnourished children of low income family. *Med J Indones* 2003;12:247-51.
- Bao S, Liu MJ, Lee B, Besecker B, Lai JP, Guttridge DC, *et al.* Zinc modulates the innate immune response *in vivo* to polymicrobial sepsis through regulation of NF- $\kappa$ B. *Am J Physiol Lung Cell Mol Physiol* 2010;298:L744-54.
- Prasad AS, Beck FW, Bao B, Fitzgerald JT, Snell DC, Steinberg JD, *et al.* Zinc supplementation decreases incidence of infections in the elderly: Effect of zinc on generation of cytokines and oxidative stress. *Am J Clin Nutr* 2007;85:837-44.
- Kahmann L, Uciechowski P, Warmuth S, Plümäkers B, Gressner AM, Malavolta M, *et al.* Zinc supplementation in the elderly reduces spontaneous inflammatory cytokine release and restores T cell functions. *Rejuvenation Res* 2008;11:227-37.
- Aydemir TB, Blanchard RK, Cousins RJ. Zinc supplementation of young men alters metallothionein, zinc transporter, and cytokine gene expression in leukocyte populations. *Proc Natl Acad Sci U S A* 2006;103:1699-704.
- Haase H, Rink L. Signal transduction in monocytes: The role of zinc ions. *Biomaterials* 2007;20:579-85.
- Rink L, Kirchner H. Zinc-altered immune function and cytokine production. *J Nutr* 2000;130:1407S-11S.
- Pierrakos C, Vincent JL. Sepsis biomarkers: A review. *Crit Care* 2010;14:R15.
- Krüttgen A, Rose-John S. Interleukin-6 in sepsis and capillary leakage syndrome. *J Interferon Cytokine Res* 2012;32:60-5.
- Nullens S, Staessens M, Peleman C, Plaek P, Malhotra-Kumar S, Francque S, *et al.* Beneficial effects of anti-interleukin-6 antibodies on impaired gastrointestinal motility, inflammation and increased colonic permeability in a murine model of sepsis are most pronounced when administered in a preventive setup. *PLoS One* 2016;11:e0152914.
- Bauss F, Dröge W, Männel DN. Tumor necrosis factor mediates endotoxic effects in mice. *Infect Immun* 1987;55:1622-5.
- Spooner CE, Markowitz NP, Saravolatz LD. The role of tumor necrosis factor in sepsis. *Clin Immunol Immunopathol* 1992;62:S11-7.
- Utomo MT, Sudarmo S, Sudiana K. Zinc supplementation in cytokine regulation during LPS-induced sepsis in rodent. *J Int Dent Med Res* 2019;5:1-6.
- Foster M, Samman S. Zinc and regulation of inflammatory cytokines: Implications for cardiometabolic disease. *Nutrients* 2012;4:676-94.
- Smith JC Jr., Butrimovitz GP, Purdy WC. Direct measurement of zinc in plasma by atomic absorption spectroscopy. *Clin Chem* 1979;25:1487-91.
- Bao B, Prasad AS, Beck FW, Snell D, Suneja A, Sarkar FH, *et al.* Zinc supplementation decreases oxidative stress, incidence of infection, and generation of inflammatory cytokines in sickle cell disease patients. *Transl Res* 2008;152:67-80.
- Bhandari N, Bahl R, Taneja S, Strand T, Mølbak K, Ulvik RJ, *et al.* Effect of routine zinc supplementation on pneumonia in children aged 6 months to 3 years: Randomised controlled trial in an urban slum. *BMJ* 2002;324:1358.
- Sandstead HH, Prasad AS, Penland JG, Beck FW, Kaplan J, Egger NG, *et al.* Zinc deficiency in Mexican American children: Influence of zinc and other micronutrients on T cells, cytokines, and antiinflammatory plasma proteins. *Am J Clin Nutr* 2008;88:1067-73.
- Cousins RJ, Liuzzi JP, Lichten LA. Mammalian zinc transport, trafficking, and signals. *J Biol Chem* 2006;281:24085-9.
- Chang KL, Hung TC, Hsieh BS, Chen YH, Chen TF, Cheng HL. Zinc at pharmacologic concentrations affects cytokine expression and induces apoptosis of human peripheral blood mononuclear cells. *Nutrition* 2006;22:465-74.
- Chu A, Foster M, Hancock D, Bell-Anderson K, Petocz P, Samman S, *et al.* TNF- $\alpha$  gene expression is increased following zinc supplementation in type 2 diabetes mellitus. *Genes Nutr* 2015;10:440.
- Meksawan K, Sermsri U, Chanvorachote P. Zinc supplementation improves anticancer activity of monocytes in type-2 diabetic patients with metabolic syndrome. *Anticancer Res* 2014;34:295-9.
- Freitas M, Fernandes E. Zinc, cadmium and nickel increase the activation of NF- $\kappa$ B and the release of cytokines from THP-1 monocytic cells. *Metallomics* 2011;3:1238-43.
- Ma L, Zhang H, Yin YL, Guo WZ, Ma YQ, Wang YB, *et al.* Role of interleukin-6 to differentiate sepsis from non-infectious systemic inflammatory response syndrome. *Cytokine* 2016;88:126-35.
- Remick DG, Bolgos G, Copeland S, Siddiqui J. Role of interleukin-6 in mortality from and physiologic response to sepsis. *Infect Immun* 2005;73:2751-7.
- Besecker BY, Exline MC, Hollyfield J, Phillips G, Disilvestro RA, Wewers MD, *et al.* A comparison of zinc metabolism, inflammation, and disease severity in critically ill infected and noninfected adults early after intensive care unit admission. *Am J Clin Nutr* 2011;93:1356-64.
- Schulte W, Bernhagen J, Bucala R. Cytokines in sepsis: Potent immunoregulators and potential therapeutic targets – an updated view. *Mediators Inflamm* 2013;2013:165974.
- Brasier AR. The nuclear factor- $\kappa$ B-interleukin-6 signalling pathway mediating vascular inflammation. *Cardiovasc Res* 2010;86:211-8.
- Elliott CL, Allport VC, Loudon JA, Wu GD, Bennett PR. Nuclear factor- $\kappa$ B is essential for up-regulation of interleukin-8 expression in human amnion and cervical epithelial cells. *Mol Hum Reprod* 2001;7:787-90.
- Dong J, Jimi E, Zeiss C, Hayden MS, Ghosh S. Constitutively active NF- $\kappa$ B triggers systemic TNF $\alpha$ -dependent inflammation and localized TNF $\alpha$ -independent inflammatory disease. *Genes Dev* 2010;24:1709-17.
- Alexander C, Rietschel ET. Bacterial lipopolysaccharides and innate immunity. *J Endotoxin Res* 2001;7:167-202.

Source of support: Nil; Conflict of interest: None Declared